HDAC9 and cancer: Developing isoform-selective HDACinhibitors represents a promising strategy to mitigate these effectswhile enhancing therapeutic efficacy by targeting specific HDAC isoformsassociated with distinct cancer types or other epigenetically drivendiseases.